• Doxycycline: From MMP Biology to Translation

  2026-08-26

  Doxycycline is more than a tetracycline antibiotic: its metalloproteinase inhibition, antimicrobial activity, and antiproliferative potential make it a versatile research tool. This article translates recent abdominal aortic aneurysm nanomedicine findings into practical guidance for mechanism-driven vascular and cancer research.

• Batimastat (BB-94): Designing Causal MMP Assays

  2026-08-25

  Batimastat (BB-94) is a broad-spectrum hydroxamate MMP inhibitor with value beyond simple enzyme blockade. This guide shows how to use it to distinguish extracellular proteolysis, localized BDNF processing, tumor invasion, and assay-specific confounders.

• Estradiol Benzoate: ERα Assay Workflows

  2026-08-25

  Build more reproducible estrogen receptor experiments with a workflow that connects controlled dosing, receptor binding, and functional readouts. Estradiol Benzoate also supports a practical bridge from structure-based screening concepts to experimentally validated estrogen receptor signaling research.

• Atrial Natriuretic Peptide: From Mechanism to Translation

  2026-08-24

  A translational framework for using rat ANP 1–11 to connect molecular signaling, natriuresis, blood pressure homeostasis, and rigorous experimental validation.

• Salvianolic acid B: Reliable Cell Assays

  2026-08-24

  Learn how Salvianolic acid B (SKU N1806) can improve the interpretability of viability, proliferation, and pulmonary fibrosis assays. This scenario-based guide covers assay interference, formulation, dose optimization, mechanistic endpoints, and practical product-selection criteria.

• Norepinephrine–Angiotensin II Conversion in Shock

  2026-08-23

  A post-hoc analysis of the ARAMIS trial estimated a median 10:1 conversion ratio between norepinephrine bitartrate equivalents and angiotensin II in patients with vasodilatory hypotension. The finding provides a practical framework for comparing vasoactive support, while the small, single-center design requires cautious application beyond the studied population.

• Ciprofloxacin–Tetracycline Antagonism at Single-Cell Scale

  2026-08-22

  The reference study shows that ciprofloxacin–tetracycline antagonism is driven primarily by improved survival under combination treatment, rather than simply by slower growth. Its microfluidic single-cell design links this protection to growth state, nutrient availability, and distinct low- versus high-SOS subpopulations.

• Atorvastatin C6405: Reliable Cell Assays

  2026-08-21

  This scenario-based guide helps researchers design more interpretable viability, proliferation, invasion, and ferroptosis experiments with Atorvastatin (SKU C6405). It connects product-specific formulation data with vascular and hepatocellular carcinoma evidence while emphasizing vehicle control, dose selection, orthogonal readouts, and practical vendor evaluation.

• MLN4924 at the Collision–Stress Interface

  2026-08-20

  MLN4924 is a selective NEDD8-activating enzyme inhibitor that connects CRL-dependent protein degradation with experimentally defined ribosome-collision stress signaling. This article presents a stress-aware framework for cancer biology research, assay controls, and interpretation beyond conventional potency benchmarking.

• Salvianolic acid B: Reliable Cell Assays

  2026-08-20

  Learn how Salvianolic acid B (SKU N1806) can improve the interpretability of viability, proliferation, and fibrosis-related assays through controlled formulation, orthogonal readouts, and mechanistic controls. This scenario-based guide connects laboratory troubleshooting with evidence on LH2 expression, collagen remodeling, and pulmonary fibrosis models.

• Salvianolic Acid B Targets LH2 in Pulmonary Fibrosis

  2026-08-19

  The reference study identifies Salvianolic acid B as a natural antifibrotic compound that reduces lysyl hydroxylase 2 expression, collagen synthesis, and pathological matrix remodeling in pulmonary fibrosis models. Its cellular and tissue-level evidence supports LH2-associated collagen cross-linking as a research target, while direct binding, selectivity, and clinical translation remain unresolved.

• NAD+ at the Caspase–Stress Interface

  2026-08-19

  A translational perspective on how Nicotinamide Adenine Dinucleotide (NAD+) research could sharpen mechanistic studies of caspase-dependent autophagy, PARP1 regulation, and DNA damage responses in cancer cells—while clearly separating evidence from forward-looking hypotheses.

• MMP-2 Liposome for Sequential Cancer Immunotherapy

  2026-08-18

  The reference study developed an MMP-2-responsive, dual-targeting liposome that sequentially delivers the PD-1 pathway-blocking peptide AUNP-12 and the IDO inhibitor NLG919. Its findings support cascade-responsive nanodelivery as a way to improve tumor localization, reactivate antitumor T-cell activity, and remodel the immunosuppressive microenvironment in breast cancer models.

• M344 Histone Deacetylase Inhibitor Workflow

  2026-08-18

  M344 combines cell permeability with potent HDAC inhibition for cancer phenotyping, radiation-response studies, and viral-latency assays. This practical guide connects concentration selection, differentiation and apoptosis readouts, formulation control, and evidence-based comparator design.

• Kanamycin Sulfate in CDI Research Design

  2026-08-17

  Learn how Kanamycin Sulfate can function as a controlled selection variable in CDI-related research without confusing bacterial growth effects with toxin inhibition. This article connects aminoglycoside assay design with the CAPE–TcdB findings reported in eLife.

7991 records 1/533 page Next 12345 下5页 Last page